BioSpace News Archive

IceCure Medical Ltd. announced that its wholly-owned subsidiary, IceCure MedTech Co., Ltd., signed an exclusive distribution agreement for IceSense3 cryoablation systems with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc and Beijing Turing Medical Technology Co. Ltd.

Company expands musculoskeletal oncology portfolio with device to treat pediatric bone cancer.

Enteris BioPharma, Inc. announced today that two posters describing clinical studies of oral formulations of leuprolide developed utilizing Enteris’ proprietary Peptelligence® platform are being presented at the annual meeting of The Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta.

Daiichi Sankyo (TSE: 4568) today announced that the first patient was dosed in the global TROPION-Breast02 phase 3 trial evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer.

Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, announced the completion of a $40 million Series B financing round.

Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society.

Todos Medical, Ltd. (OTCQB: TOMDF) , a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has completed validation of a 27-pathogen urinary tract infection (UTI) PCR precision medicine panel.

Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced the resubmission of the Company’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational agent terlipressin to treat adults with hepatorenal syndrome (HRS) .

Avid Bioservices, Inc. today announced that the company is further expanding its process development capacity for its mammalian cell business.

Sirona Biochem Corp. is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 and related family of compounds.